Exploring the content and psychometric validity of clinical outcome assessments in renal cell carcinoma versus the patient reported symptoms and impacts

Presented at ISPOR 2024

I Petit¹, L Eliasson², B Romero³, C Patel², A Di Rosa³, J Quinn¹

¹ Debiopharm SA, Switzerland
²Sprout Health Solutions Limited, UK
³Sprout Health Solutions Limited, US